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IgG was traditionally thought to neutralize virions by blocking
their attachment to or penetration into mucosal epithelial cells,
a common site of exposure to viruses. However, we describe an
intracellular neutralizing action for an inﬂuenza hemagglutinin-
speciﬁc monoclonal antibody, Y8-10C2 (Y8), which has neutraliz-
ing activity only at an acidic pH. When Y8 was applied to the
basolateral surface of Madin–Darby canine kidney cells expressing
the rat neonatal Fc receptor for IgG (FcRn), it signiﬁcantly reduced
viral replication following apical exposure of the cell monolayer
to inﬂuenza virus. Virus neutralization by Y8 mAb was dependent
on FcRn expression and its transport of IgG. As both FcRn and Y8
mAb bind their partners only at acidic pH, the Y8 mAb is proposed
to carry out its antiviral activity intracellularly. Furthermore, the
virus, Y8 mAb, and FcRn colocalized within endosomes, possibly
inhibiting the fusion of viral envelopes with endosomal mem-
branes during primary uncoating, and preventing the accumula-
tion of the neutralized viral nucleoprotein antigen in the nucleus.
Prophylactic administration of Y8 mAb before viral challenge in
WT mice, but not FcRn-KO mice, conferred protection from lethal-
ity, prevented weight loss, resulted in a signiﬁcant reduction in
pulmonary virus titers, and largely reduced virus-induced lung pa-
thology. Thus, this study reveals an intracellular mechanism for
viral neutralization in polarized epithelial cells that is dependent
on FcRn-mediated transport of neutralizing IgG.
The neonatal Fc receptor, FcRn, plays a central role in IgGbiology at all stages of life. It is the only known Fc receptor
able to transport IgG across cell barriers. At the perinatal stage,
FcRn confers the newborn with humoral immunity by trans-
porting maternal IgG across placental and/or neonatal intestinal
epithelial cells (reviewed in refs. 1–3). By transcytosing IgG
across the vascular endothelium at all stages of life, FcRn
ensures the extravascular bioavailability of IgG (1). Finally, by
transcytosing IgG across the mucosal epithelium, FcRn provides
a line of humoral defense at the mucosal surfaces (3).
In addition to its transcytotic function, FcRn plays a critical
role in serum IgG homeostasis by recycling IgG away from
a catabolic pathway in vascular endothelium, thus extending its
lifespan in circulation and ensuring long-lasting protective im-
munity after infection (1, 2). A hallmark of FcRn is that it binds
IgG at acidic pH (≤6.5) and releases IgG at neutral or higher
pH (4). In the majority of cell types, FcRn resides primarily in
early acidic endosomal vesicles (5, 6); FcRn binds to IgG that
enters the cell by pinocytosis or endocytosis. Subsequently, FcRn
efﬁciently recycles IgG back to the plasma membrane or trans-
cytoses it to the opposite plasma membrane, where the near-
neutral pH of the extracellular environment causes IgG release
from FcRn. Any pinocytosed or endocytosed proteins, including
IgG, that are not rescued in this manner are efﬁciently trafﬁcked
to the lysosomes for degradation (1–3).
Epithelial monolayers lining the mucosal surfaces polarize into
two separate plasma membrane domains, the apical and baso-
lateral, which are separated by intercellular tight junctions at the
apical poles. The vast mucosal surfaces represent major sites of
potential attack by invading pathogens. Receptor-mediated en-
docytosis of viruses and postendocytic membrane fusion has long
been accepted as a cell entry mechanism for many viruses (7).
For enveloped viruses, fusion of the viral lipid bilayer with the
membrane of an acidic endosome is generally catalyzed by
a “fusion protein” on the viral surface (8). Inﬂuenza A virus
infection begins with the interaction of virions with cell surface
sialic acid residues (9) primarily mediated by hemagglutinin
(HA). After binding, virions are internalized through endocytic
pathways (10). The acidic pH within the endosomes induces
a conformational change in the viral HA, which in turn triggers
fusion between the viral envelope and the endosomal mem-
branes. Subsequently, the viral matrix and viral ribonucleopro-
tein (vRNP) are ejected into the cytoplasm and the vRNP is
actively imported into the nucleus. Viral proteins produced in
the cytoplasm assemble with replicated viral RNA and bud from
the cell membrane.
Mucosal antibody provides a primary line of defense against
pathogen invasion (11). Although studies have shown that FcRn
is responsible for shuttling IgG (12–14), the exact role of FcRn-
mediated IgG transport in mucosal protection remains elusive.
Intriguingly, acidic endosomes appear to be the primary com-
partment in which FcRn resides and functions, and endocytosed
virions initiate fusion of their envelopes within these compart-
ments. Therefore, the endosome would be an ideal site for the
transcytosed IgG to meet internalized virions within polarized
epithelial cells. This led us to speculate that FcRn trafﬁcs ex-
tracellular virus-speciﬁc IgG to the endosomes of epithelial cells,
where it prevents virus replication. To investigate this hypothesis,
we used an mAb, Y8-10C2 (Y8), that binds to the monomeric
but not trimeric form of inﬂuenza HA, corresponding to con-
formational changes induced by acidic pH (15). Our data show
that FcRn-mediated transport of Y8 mAb results in the neu-
tralization of viral infection in the epithelial endosomes by
blocking viral envelope fusion with endosomal membranes, sub-
Author contributions: Y.B., L.Y., and X.Z. designed research; Y.B., L.Y., D.B.T., H.S., and
D.Z. performed research; P.J.B. and D.C.R. contributed new reagents/analytic tools; Y.B.,
L.Y., P.J.B., D.C.R., and X.Z. analyzed data; and D.B.T., P.J.B., D.C.R., and X.Z. wrote
the paper.
The authors declare no conﬂict of interest.
This article is a PNAS Direct Submission.
1Y.B. and L.Y. contributed equally to this work.
2To whom correspondence may be addressed E-mail: bjorkman@caltech.edu or xzhu1@
umd.edu.
This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.
1073/pnas.1115348108/-/DCSupplemental.
18406–18411 | PNAS | November 8, 2011 | vol. 108 | no. 45 www.pnas.org/cgi/doi/10.1073/pnas.1115348108
sequently resulting in the arrest of viral replication. These data
suggest that FcRn/IgG plays a unique role in the intracellular
defense, in addition to the role it plays extracellularly. This ﬁnding
may have implications for the design of vaccines or antibody-
based therapies.
Results
FcRn-Mediated IgG Neutralization of Inﬂuenza Virus. Transcytosis
of the FcRn-IgG complex can be faithfully recapitulated in po-
larized Madin–Darby canine kidney (MDCK) cells stably trans-
fected with rat FcRn and β2m (MDCK-FcRn) (5). Additionally,
MDCK is a classic model cell line for replicating inﬂuenza virus.
Y8 mAb can only detect PR8 HA in conformational forms in-
duced by an acidic pH (Fig. S1). We thus selected MDCK-FcRn
as a cell-based model system to test the hypothesis. Y8 mAb or
an irrelevant IgG was added to the basolateral chamber of
MDCK-FcRn to initiate transcytosis (Fig. S2). Subsequently,
PR8 virus was added to the apical side to initiate infection. Viral
yields were measured in the apical medium 24 h later by a 50%
tissue culture infective dose (TCID50) assay. The results showed
that mAb Y8 reduced the yield of PR8 virus approximately 100-
fold, but not in an MDCK-vector or IgG control monolayer (Fig.
1A). The extent of viral replication was further assessed by ex-
amining the expression of the inﬂuenza nucleoprotein (NP)
gene. FcRn-mediated transcytosis of Y8 IgG, but not control
IgG, signiﬁcantly reduced the expression level of NP gene (Fig.
S3). These data further suggest that the intracellular inhibition of
virus replication is dependent on the transepithelial ﬂux of IgG.
To further test whether the intracellular neutralization of in-
ﬂuenza virus by Y8 mAb in MDCK-FcRn cells was dependent
on FcRn-mediated IgG transcytosis, we performed two experi-
ments. First, we used MDCK cells expressing a chimeric FcRn
and GFP, which is unable to transcytose IgG (5), and we veriﬁed
this result (Fig. S4A). Y8 mAb added to the basolateral chamber
of MDCK-FcRn-GFP monolayers did not signiﬁcantly reduce
virus titers in comparison with those of control IgG-treated cells
(Fig. 1B). In contrast, MDCK-FcRn cells produced signiﬁcantly
fewer viral progeny when incubated basolaterally with Y8 mAb.
Second, the virus titers in MDCK-FcRn/IgG cells that were
pretreated with nocodazole reached comparable levels to those
observed in untreated MDCK-vector cells (Fig. S4 B and C). We
conclude that the intracellular neutralization of virus by Y8 mAb
is dependent on FcRn-mediated IgG transport by polarized
epithelial cells.
Colocalization of FcRn, Virus, and IgG in Endosomal Compartment.
FcRn binding to IgG and Y8 mAb binding to PR8 virions both
occur only at acidic pH. Acidic conditions also cause fusion
between the endosomal membrane and the viral envelope.
We speculated that Y8 mAb transported into these endosomal
compartments by FcRn might interact with virus particles
endocytosed from apical epithelial surfaces. To test this possi-
bility, we performed confocal analysis of conﬂuent MDCK-FcRn
cells that were incubated with Y8 mAb and further infected with
biotin-labeled PR8 virus. As expected, the staining appeared in
punctuate and vesicular patterns (Fig. S5). Pair-wise colocaliza-
tion of PR8 virus or FcRn with Y8 mAb showed signiﬁcant
colocalization (yellow, Fig. S5, Upper) in all cases. Furthermore,
both Y8 mAb (blue, Fig. S5) and PR8 virus (red, Fig. S5) colo-
calized with the early endosomal marker EEA1 (green, Fig. S5)
in three-color confocal experiments (white, Fig. S5, Lower). Most
importantly, the colocalization results were conﬁrmed by staining
MDCK-FcRn cells that were inoculated basolaterally with Y8
mAb and apically infected with PR8 (Fig. 2). A Z-stack recon-
structed view showed that the colocalization only occurred on
the apical sides, suggesting Y8 IgG had been transported from
the basolateral to apical domain.
Y8 mAb Neutralizes Viral Replication by Blocking Trafﬁcking of
Inﬂuenza vRNPs to the Nucleus. When inﬂuenza particles are
endocytosed into endosomes, the acidic pH triggers fusion be-
tween the viral envelope and the endosomal membranes and
release of vRNPs into the cytoplasm, with subsequent travel to
the nucleus to initiate replication. If the Y8 mAb acts by pre-
venting viral envelope fusion with the endosomal membrane, it
should prevent the trafﬁcking of vRNPs to the nucleus. To test
this, infected cells were stained with mAb anti-EEA1, an early
endosome marker, or anti-NP protein to visualize vRNP traf-
ﬁcking to the nucleus. We were able to detect PR8 NP proteins
(red, Fig. 3A) in the nucleus in control IgG-treated cells 1 h after
infection (Fig. 3A), but not in the Y8 mAb-treated cells
(Fig. 3A). Interestingly, the overall density of NP staining was
signiﬁcantly increased in control IgG-treated cells (Fig. 3A). One
possible explanation is that NP was made rapidly in cells that
Fig. 1. Neutralization of inﬂuenza PR8 virus in MDCK-FcRn cells by Y8 mAb.
Cells (1 × 105/well) were grown in a 0.4-μm transwell insert and allowed to
polarize. (A) Neutralization of PR8 virus by Y8 mAb transcytosis. Y8 mAb or
IgG2a isotype (400 μg/mL) was added to the basolateral chamber for 2 h at
37 °C; subsequently, PR8 virus (100 pfu/cell) was added to the apical chamber
for 1.5 h at 4 °C, then switched to 37 °C for 45 min. Cells in both chambers
were completely washed of residual IgG to remove adherent virus particles.
Monolayers were then incubated for an additional 24 h at 37 °C. The amount
of PR8 virus in the apical medium was analyzed by TCID50 assay. (B) Neu-
tralization of PR8 virus by Y8 mAb is dependent on IgG transcytosis. Y8 mAb
(400 μg/mL) was added to the basolateral chamber of MDCK-FcRn, MDCK-
FcRn-GFP, or control cells for 2 h at 37 °C. PR8 virus was subsequently added
to the apical side for 1.5 h at 4 °C, and then cells were switched to 37 °C for
another 45 min to allow for infection. The remaining procedures were
performed as in A. *P < 0.05 and **P < 0.01.
Fig. 2. Intracellular colocalizations of Y8 mAb, FcRn, PR8 virus, and
endosome. Colocalization of FcRn, EEA1, IgG, and PR8 virus in MDCK-FcRn
cells. Cells were grown in 0.4-μm inserts and allowed to polarize. Y8 mAb
(400 μg/mL) was added to the basolateral side for 2 h at 37 °C, and sub-
sequently, biotin-PR8 virus (100 pfu/cell) was added to the apical side for
1.5 h at 4 °C. Cells were then incubated for 45 min at 37 °C and thoroughly
washed to remove the residual IgG. Cells were ﬁxed and permeabilized.
MDCK-FcRn cells were incubated with mouse anti-FcRn (1G3 mAb) or mAb
anti-EEA-1 (5 μg/mL) or ZO-1 (5 μg/mL), respectively, followed by Alexa Fluor
488- or Alexa Fluor 555-conjugated IgG of the corresponding species. XY
sections are taken at the level of the ZO-1 staining, and the XZ sections are
shown (Lower). The ZO-1 staining (blue) indicates the tight junctions at the
apical pole of the MDCK-FcRn cells. Colocalization of red and green signals
creates a yellow-orange color. (Scale bars: 5 μm.)











were infected with this amount of virions, so the observed
staining may represent newly synthesized NP. However, in at
least one previous study, newly synthesized NP was not detected
until 4 h after infection, with the maximum synthesis occurring at
approximately 8 to 9 h (16).
To further investigate the fate of virus particles, anti–lyso-
some-associated membrane glycoprotein-2 (LAMP-2), a lyso-
somal marker, and anti-NP mAbs were used to follow virion
trafﬁcking to nuclear or lysosomal sites. Transport of the virus
particles to the lysosomes was negligible in control IgG-treated
MDCK-FcRn cells during the incubation periods indicated (Fig.
3B). However, the colocalization (yellow, Fig. 3B) of LAMP-2
and virus particles became more prominent at 45 min in Y8
mAb-treated cells, suggesting that this antibody promotes the
trafﬁcking of virus particles into the lysosomes (Fig. 3B). Pearson
correlation coefﬁcient analysis indicated a signiﬁcant colocali-
zation of viral NP protein with endosomal (Fig. 3C), lysosomal
(Fig. 3D), and nucleus markers (Fig. 3E). Taken together, these
data strongly suggest that the Y8 mAb prevents inﬂuenza virus
entry into the nucleus, possibly by retaining the virus in endocytic
compartments and by inhibiting the fusion of virus envelope and
endosomal membranes, ultimately resulting in the delivery of
these particles to lysosomes for degradation.
Prophylactic Efﬁcacy of Y8 mAb Against PR8 Inﬂuenza Challenge in
Vivo. Given FcRn expressed in the airway and mediated IgG
transport across the airway mucosal barrier (Figs. S6 and S7), it
was of interest to know whether passive transfer of Y8 mAb
could confer protection from PR8 infection in mice. Groups of
ﬁve WT and ﬁve FcRn-KO mice each received 100 μg of puriﬁed
Y8 mAb via an intraperitoneal injection. Control groups of WT
mice received isotype-matched IgG or sterile PBS solution. All
mice were intranasally challenged 4 h later with a lethal dose
(500 pfu) of PR8 virus. Because the serum half-life of IgG is
greatly reduced in FcRn-KO mice (17, 18), we injected the FcRn
KO mice daily with 25–57.5 μg of Y8 mAb to compensate for
IgG degradation. This supplementation strategy was ﬁrst con-
ﬁrmed by injecting biotin-labeled IgG in a pilot experiment. In
this way, the concentrations of Y8 mAb were expected to be
similar between WT and FcRn-KO mice. Survival rates (Fig. 4A)
and body weight losses (Fig. 4B) were then monitored. All WT
animals that received Y8 mAb survived, whereas only 40% of the
Fig. 3. Y8 mAb blocks the entry of PR8 ribonucleoprotein into the nucleus following infection. MDCK-FcRn cells were incubated with Y8 mAb or control
IgG2a (400 μg/mL) for 2 h. Cells were then infected with PR8 virus at a multiplicity of infection of 100 pfu/cell at 4 °C for 1.5 h to allow virus attachment.
Subsequently, infected cells were shifted to 37 °C to allow virus infection at indicated time points. Cells were ﬁxed, permeabilized, and blocked before
staining with mAb anti–EEA-1 (5 μg/mL) (A) or anti–LAMP-2 (5 μg/mL) (B) followed by Alexa Fluor 488- or Alexa Fluor 555-conjugated IgG. NP proteins were
stained red by HB-65 mAb for the appearance of PR8 at indicated time. The nucleus is stained with DAPI (blue). (Scale bar: 5 μm.) Pearson colocalization
coefﬁcient was calculated to represent the colocalization between NP protein and EEA1 (C), LAMP-2 (D), and DAP1 (E) in PR8-infected MDCK-FcRn cells
treated with Y8 mAb or control IgG at different time points following infection. Ten cells were analyzed from at least three different optical regions at each
time point by using LSM5 image examiner software (Zeiss).**P < 0.01 and ***P < 0.001.
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animals in the FcRn-KO group survived (P < 0.05). The majority
of animals that received irrelevant IgG or PBS solution died of
infection within 6 d after challenge. Therefore, the administra-
tion of Y8 mAb in the WT mice was clearly associated with
a survival beneﬁt compared with control animals. Although the
FcRn-KO mice receiving the Y8 mAb showed a trend toward
increased survival, the increase was not signiﬁcantly different
from control animals. In addition, WT animals treated with Y8
mAb did not signiﬁcantly lose body weight, whereas the mean
weight loss in the control group was approximately 30% by the
time the mice died or were euthanized (P < 0.01). FcRn-KO
mice that received Y8 mAb showed similar decreases in body
weight as the control animals, with a 25% mean weight loss (Fig.
4B). In addition, all animals were assessed for viral load in the
lungs at day 1 (Fig. 4C) or day 5 (Fig. 4D) after infection, after
necropsy. The levels of virus in the lungs of WT mice, but not
FcRn-KO mice treated with Y8 mAb, were 2.5 to 3 log10 TCID50
lower than that in the control group (both P < 0.01).
Pathological results were in accordance with the ﬁndings de-
scribed earlier. No lesions were present in the lungs of mock-
infected mice (Fig. 5A, normal control). In H36-4 (Fig. S1 and SI
Results) mAb-treated animals, the loss of infectivity attributable
to the combined inhibition of attachment and inhibition of fusion
was sufﬁcient to account for the extent of neutralization caused
by relatively low concentrations of H36-4 mAb. WT animals that
received Y8 mAb showed much less pulmonary pathology, such
as edema or hemorrhagic appearance, or showed such lesions at
a lower grade of severity, compared with control antibody- or
PBS solution-treated animals (Fig. 5A). Examination of lungs in
mice that received Y8 mAb on day 6 or 8 after infection revealed
that mice did not develop apparent inﬂammatory changes, al-
though a slightly increased lymphocytic perivascular cufﬁng was
observed (Fig. 5B, images 5 and 7). Examination of lungs in mice
that received H36-4 mAb on day 6 or 8 after infection revealed
a similar level of resolution (Fig. 5B, image 3). In contrast, FcRn
KO mice that received Y8 developed peribronchiolar pneumo-
nia that increased in severity, and a necrotizing bronchitis and
bronchiolitis also appeared at this time point (Fig. 5B, images
6 and 8). Mice that received PBS solution and irrelevant IgG had
continued peribronchiolar pneumonia and necrotizing bron-
chiolitis at day 6 after infection; the pneumonia was more wide-
spread (Fig. 5B, images 2 and 4). The unprotected animals all
died at day 6 to 7 after infection. Overall, these ﬁndings show that
prophylactically administered Y8 mAb confers protection against
lethal PR8 challenge, prevents mortality and viral replication, and
reduces pulmonary pathology in an FcRn-dependent manner.
Discussion
IgG is the predominant Ig isotype present in the lungs (19). In the
context of inﬂuenza virus, passive immunization by vertical ac-
quisition (20) or passive transfer (21, 22) demonstrates a clear role
for virus-speciﬁc murine or humanized IgG antibodies in pro-
phylaxis and therapy in both animal models as well as in infant
humans. However, the precise cellular mechanisms by which these
antibodies protect against viral infection and/or propagation re-
main elusive.Although the direct neutralization of viral particles is
believed to be the primary function of antibodies in antiviral im-
munity, IgG is also efﬁcient atﬁxing complement and binding toFc
receptors on cells (11, 23). Indeed, “nonneutralizing” antibody-
dependent cellular cytotoxicity has been demonstrated in viral
infection (24). However, these functions all require extracellular
interactions, which should not occur between Y8 mAb and HA
because this antibody is unable to bind HA at neutral pH. In this
study, we show that anti-inﬂuenza IgG antibodies, traditionally
considered to be nonneutralizing IgG, are in fact capable of
blocking viral infection in polarized epithelial cells via a mecha-
nism that is dependent on FcRn-mediated transport of IgG.
To directly determine whether Y8 interferes within inﬂuenza
infection, the intracellular neutralizing potential of Y8 mAb was
evaluated by mimicking the mucosal epithelial barrier in vitro.
Y8, but not control IgG, signiﬁcantly reduced PR8 viral repli-
cation, suggesting that the blocking of viral replication by Y8 is
Fig. 4. PR8 HA-speciﬁc Y8 mAb protected mice from virus infection. (A and B) Severity of infection in mice challenged with PR8 virus. Groups of ﬁve WT and
FcRn-KO mice were intraperitoneally injected with 100 μg Y8 mAb or control IgG. One group of ﬁve mice was mock-injected with PBS solution. Four hours
later, mice were intranasally challenged with 500 pfu of PR8 virus. The mice were monitored for 10 d. FcRn-KO mice were injected daily with 25–57.5 μg Y8 or
control IgG to compensate for IgG catabolism. (A) Survival rate was assessed by recording whether the mice died from the infection. Percentage of mice
protected on the indicated days was calculated as the number of mice surviving divided by the number of mice in each group and averaged over three similar
experiments (n = 15). The mice were also weighed daily to monitor illness, as deﬁned by percent weight loss (B). For virus titration, lungs were harvested at
day 1 (C) or day 5 (D) after infection and homogenized. The amount of PR8 virus in the supernatant was analyzed by TCID50. Data shown are the means of
three independent experiments, with ﬁve mice per group (**P < 0.01).











dependent on transepithelial transcytosis of IgG by FcRn. Fur-
thermore, Y8 colocalized with virions and FcRn inside endosomes,
consistent with previous studies of the intracellular colocalization
of these proteins. Most importantly, Y8 mAb did not bind the
PR8 virus at neutral pH, excluding the possibility that the Y8
neutralized virus in an extracellular environment. Therefore, the
Y8 mAb most likely interrupted viral replication during its en-
counter with viral particles in acidic endosomal compartments.
We further examined the capacity of Y8 mAb to inhibit PR8
virus replication and reduce lung inﬂammation when Y8 mAb
was administered to WT and FcRn-KO mice. Y8 mAb in WT
mice provided strong protection from lethality, prevented weight
loss, provided a signiﬁcant reduction in pulmonary virus titers,
and largely reduced virus-induced inﬂammation in the lungs.
However, it should be noted that Y8 conferred some (albeit
signiﬁcantly less) protection from postinfection lethality and
weight loss in FcRn-KO mice. This FcRn-independent effect
may be a result of ﬂuid-phase uptake of the Y8 mAb into cells
and endosomal entry in vivo. Overall, our results support a mech-
anism in which FcRn mediates the intracellular transport of anti-
inﬂuenza IgG antibodies for endosomal neutralization sites in
polarized epithelial cells.
What are the critical steps at which the Y8 mAb interferes with
the viral life cycle during its trafﬁcking by FcRn? An acidic pH is
critical for FcRn binding to Y8 and for Y8 to interact with HA. Y8
mAb was shown to bind to internalized virus but not to virus
absorbed to the cell surface (Fig. S1). Thisﬁnding is consistentwith
the fact that Y8 can bind to HA only following conformational
changes caused by a low pH such as those that occur inside
endosomes (15, 25). Y8 might therefore sterically block an in-
teraction between the endosomal membrane and a region of the
inﬂuenza HA responsible for fusion. As such, FcRn may organize
IgG in the endosome in an orientation that facilitates the in-
teractionwith viralHA.Alternatively, FcRnmight simply increase
the endosomal concentrations of IgG to levels that more effec-
tively block viral fusion.
FcRn-mediated transport of IgG can be divided into several
steps: IgG pinocytosis from the basolateral membrane to ba-
solateral recycling endosomes, translocation from basolateral
early endosomes to apical recycling endosomes (ARE), and ﬁ-
nally, IgG recycling between the ARE and the apical plasma
membrane (1, 2). Therefore, transcytosis should result in the
accumulation of FcRn/Y8 mAb in the ARE. Intracellular neu-
tralization is likely to result from the fusion of transcytotic
vesicles containing Y8 mAb with vesicles containing endocy-
tosed virions, suggesting that Y8 mAb blocks acid-induced fu-
sion of the viral and endosome membranes required for vRNP
entry into the cytoplasm and nucleus. In the present study, in-
hibition of this fusion process was strongly suggested by the fact
that NP antigen from Y8 IgG-neutralized virus, unlike that of
nonneutralized virus, did not accumulate in the nucleus; in-
stead, it was enriched in the lysosomes. Live cell imaging
analyses of endothelial cells provides strong evidence that FcRn
can trafﬁc its ligands to the lysosomes (26). FcγRI and FcγRIII
engagement by IgG–bacteria immune complexes target in-
tracellular bacteria to lysosomes in macrophages for degradation
by a process strictly dependent on protein kinases involved in FcR
intracellular signaling (27). Although these mechanisms are found
in endothelial cells or macrophages, it is interesting to determine
whether similar intracellular signaling and trafﬁcking pathways
operate in polarized epithelial cells to target antibody-coated
viruses to lysosomes. Furthermore, although we used a highly pH-
dependent mAb to demonstrate intracellular neutralization,
a pH-independent IgG that binds HA at a location that prevents
a conformational change required for fusion might function in
both extracellular neutralization and, upon encountering virus
within endosomes, intracellular neutralization.
It is intriguing that Y8 mAb binds to the globular but not the
fusion domain of the stalk region of inﬂuenza HA (15). It has
been shown that membrane fusion mediated by the inﬂuenza HA
requires the concerted action of at least HA trimers (28). By
binding to low pH-induced monomeric HA molecules, Y8 mAb
might prevent a structural transition of HA required for fusion,
as shown in a previous study (29). Thus, Y8 mAb may neutralize
intracellularly because it blocks fusion and egress from endo-
somes, resulting in the transport of virions to the lysosome for
destruction. It is possible that other IgG antibodies with a
broader spectrum of action or directed against the HA stalk
regions containing the fusion domain might work similarly, or
even more effectively, by FcRn-dependent intracellular neu-
tralization mechanisms at the mucosal surface. It would be
interesting to know if intracellular neutralization would be effec-
tive against a broad spectrum of inﬂuenza subtypes and antigenic
drift variants as a result of the possible conservation of the an-
tibody recognition site in the fusion domain. For example,
antibodies can broadly recognize a highly conserved inﬂuenza
virus epitope in the stalk regions of inﬂuenza HA (30, 31); a
vaccine based on the conserved HA stalk domain provided full
protection against death and partial protection against disease
following lethal viral challenge (32). Thus, heterotypic immunity
probably involves several distinct immunological pathways, and
this study illustrates that FcRn-mediated IgG transcytosis con-
tributes to an intracellular neutralization mechanism.
The current paradigm for antibody-mediated mucosal immu-
nity is that polymeric IgA receptor-mediated transcytosis of di-
meric IgA releases secretory IgA into mucosal secretions by
proteolytic cleavage. This transport process makes it possible for
secretory IgA to block the binding of viruses to their entry
receptors on the cell surface and to neutralize intracellular
viruses (33–35). In this study, FcRn-mediated IgG transcytosis
provides a mechanism for eliminating intracellular pathogens
Fig. 5. Lung pathologic ﬁndings following PR8 virus challenge. (A) Gross
pathology of the lung. The lung exhibited edema and a hemorrhagic ap-
pearance in the absence of Y8 mAb inoculation or in FcRn-KO mice in-
oculated with Y8 mAb. H36-4 mAb was used as a positive control. (B)
Histopathology in the lung of PR8-infected mice at 6 or 8 d. Inﬂammation
was most severe in infected mice on day 6. After infection with PR8, WT mice
treated with Y8 (WT/Y8) or H36 mAb (WT/H36) exhibited few focal areas of
epithelial necrosis and peribronchial hemorrhage; however, the WT mice
treated with PBS solution or irrelevant IgG, or FcRn-KO mice inoculated with
Y8 mAb, showed severe peribronchial inﬂammation and bronchiolar ne-
crosis with necrotic epithelial cells present in the lumen, and submucosal
edema and vascular congestion. A mixed inﬁltration of inﬂammatory cells
was present throughout at day 6 after infection. All unprotected animals
died between days 6 and 7 after infections. Positive control infected mice
had similar bronchiolar necrosis as control IgG-inoculated mice. Mock-
infected mice had no lesions.
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without destroying epithelial integrity (Fig. S8). This protective
mechanism is determined by intracellular interactions between
IgG and viral proteins enabled by the FcRn-mediated transport
of IgG, by the speciﬁcity of the IgG for a particular viral com-
ponent, and by the life cycle of the virus within mucosal epi-
thelial cells. Similar intracellular neutralization mechanisms
might be applicable for HIV (36) as well as bacteria (37). Re-
cently, a cytosolic IgG receptor, tripartite motif-containing 21,
bound and targeted incoming antibody–virus complexes to the
proteasome via its E3 ubiquitin ligase activity (38). Our ﬁnding
that FcRn efﬁciently delivers IgG to intracellular vesicles may
provide an endosomal route for access to this cytosolic receptor.
A greater understanding of the mechanisms by which strongly
inhibitory antibodies act intracellularly may inﬂuence the design
of novel vaccines (39) or antibody-based therapies.
Methods
All cells were grown in DMEM completemedium in 5%CO2 at 37 °C. Inﬂuenza
A virus (strain A/Puerto Rico/8/1934 H1N1) was grown in 10- to 11-d-old em-
bryonated chicken eggs. All PR8 virus-speciﬁc mAbs and staining antibodies
were purchased. The FcRn-KO mice in a C57BL/6 background were from
Jackson Laboratory. All animal studies were approved by the institutional
animal care and use committee at the University of Maryland. SI Methods
provides further details.
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